Membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis | |
---|---|
Other names: Mesangiocapillary glomerulonephritis[1] | |
![]() | |
Micrograph of glomerulus in membranoproliferative glomerulonephritis with increased mesangial matrix and increased mesangial cellularity.Kidney biopsy.PAS stain. | |
![]() | |
Specialty | Nephrology |
Symptoms | Foamy urine,blood in the urine,swelling[1] |
Complications | High blood pressure,low red blood cells,kidney failure[1] |
Usual onset | Children and young adults[1] |
Types | Primary (type I, II, III), secondary[1] |
Causes | Unknown,infections,autoimmune disorders,cancer,liver disease, certain drugs[1] |
Diagnostic method | Kidney biopsy[2] |
Differential diagnosis | Minimal change disease,lupus nephritis,diabetic nephropathy,focal segmental glomerulosclerosis[3] |
Treatment | Steroids,cyclophosphamide,ASA,kidney transplant,plasma exchange[1][2] |
Prognosis | Generally poor[2] |
Frequency | Uncommon[1] |
Membranoproliferative glomerulonephritis (MPGN) is a pattern of injury of theglomeruli of thekidneys.[1] Symptoms may includefoamy urine,blood in the urine, orswelling.[1] Generally it gradually worsens over time.[1] Complications often includehigh blood pressure,low red blood cells, andkidney failure.[1]
The cause can be unknown or it can occur as a result ofinfections,autoimmune disorders,cancer,liver disease, or certain drugs.[1] The underlying mechanism is believed to involveimmune complexes building up in the kidneys and activating thecomplement system.[1] This results inmesangial cell growth with thickening of the walls of thesmall blood vessels.[1] Diagnosis is bykidney biopsy.[2]
The best method of management is unclear.[1] Treatment may include the use ofsteroids,cyclophosphamide, oraspirin.[1][2]Plasma exchange has been tried.[1] While akidney transplant may be carried out, the disease may reoccur afterwards.[1] It is uncommon for the disease to resolve without treatment.[1] Outcomes are generally poor.[2]
MPGN is uncommon.[1] It most commonly occurs in children and young adults.[1] Males and females are affected equally frequently.[1] It makes up about 4% of primary kidney causes ofnephrotic syndrome in children and 7% in adults.[1] MPGN was first described in 1965 by Gotoff and West.[4]
Signs and sympoms
Symptoms may includefoamy urine,blood in the urine, orswelling.[1] Generally it gradually worsens over time.[1] Complications often includehigh blood pressure,low red blood cells, andkidney failure.[1]
Cause
The cause can be unknown or it can occur as a result ofinfections,autoimmune disorders,cancer,liver disease, or certain drugs.[1]
Pathophysiology

Membranoproliferative glomerulonephritis involves deposits at the intraglomerular mesangium.
It is also the mainhepatitis C associated nephropathy.
It also is related to a number of autoimmune diseases, prominentlysystemic lupus erythematosus (SLE). Also found withSjögren syndrome,rheumatoid arthritis, inherited complement deficiencies (esp C2 deficiency),scleroderma,Celiac disease.[5]
Diagnosis
The GBM is rebuilt on top of the deposits, causing a "tram tracking" appearance under the microscope.[6] Mesangial cellularity is increased.[7]
Classification
There are three types of MPGN, but this classification is becoming obsolete as the causes of this pattern are becoming understood.
Type I
Type I, the most common by far, is caused byimmune complexes depositing in the kidney. It is characterised by subendothelial and mesangial immune deposits.
It is believed to be associated with theclassical complement pathway.[8]
Type II
The preferred name is "dense deposit disease."[9] Most cases of dense deposit disease do not show a membranoproliferative pattern.[10] A 2012 review considers DDD to be in a continuum withC3 glomerulonephritis,[11] one reason the use of the type I to type III classification system is falling out of favour.[citation needed]
Most cases are associated with the dysregulation of thealternative complement pathway.[12][13]
DDD is associated with deposition of complement C3 within the glomeruli with little or no staining for immunoglobulin. The presence of C3 without significant immunoglobulin suggested to early investigators that DDD was due to abnormal activation of the complement alternative pathway (AP). There is now strong evidence that DDD is caused by uncontrolled AP activation.[14]
Spontaneous remissions of MPGN II are rare; approximately half of those affected with MPGN II will progress toend stage renal disease within ten years.[15]
In many cases, people with MPGN II can developdrusen caused by deposits withinBruch's membrane beneath theretinal pigment epithelium of the eye. Over time, vision can deteriorate, and subretinal neovascular membranes, macular detachment, andcentral serous retinopathy can develop.[16]
Type III
Type III is very rare, it is characterized by a mixture of subepithelial and subendothelial immune and/or complement deposits. These deposits elicit an immune response, causing damage to cells and structures within their vicinity. Has similar pathological findings of Type I disease.[17]
A candidate gene has been identified onchromosome 1.[18]
Complement component 3 is seen underimmunofluorescence.[19] it is associated with complement receptor 6 deficiency.
Differential diagnosis
The histomorphologicdifferential diagnosis includestransplant glomerulopathy andthrombotic microangiopathies.
Treatment
Primary MPGN is treated with steroids, plasma exchange and other immunosuppressive drugs.Secondary MPGN is treated by treating the associated infection, autoimmune disease or neoplasms. Pegylated interferon and ribavirin are useful in reducing viral load.[20]
References
- ↑1.001.011.021.031.041.051.061.071.081.091.101.111.121.131.141.151.161.171.181.191.201.211.221.231.241.251.261.27Alchi, B; Jayne, D (August 2010). "Membranoproliferative glomerulonephritis".Pediatric nephrology (Berlin, Germany).25 (8):1409–18.doi:10.1007/s00467-009-1322-7.PMID 19908070.
- ↑2.02.12.22.32.42.5Membranoproliferative Glomerulonephritis - Genitourinary Disorders. Merck Manual.Archived from the original on 26 November 2020. Retrieved25 January 2021.Archived 26 November 2020 at theWayback Machine
- ↑Floege, Jurgen; Johnson, Richard J.; Feehally, John (2010).Comprehensive Clinical Nephrology E-Book. Elsevier Health Sciences. p. 253.ISBN 978-0-323-08133-7.Archived from the original on 2021-08-29. Retrieved2021-01-25.
- ↑Wolstenholme, G. E. W.; O'Connor, Maeve (2009).Protein Turnover. John Wiley & Sons. p. 285.ISBN 978-0-470-71759-2.Archived from the original on 2021-08-28. Retrieved2021-01-25.
- ↑"Archive copy".Archived from the original on 2021-04-10. Retrieved2019-05-06.
{{cite web}}
: CS1 maint: archived copy as title (link)Archived 2021-04-10 at theWayback Machine - ↑"Membranoproliferative_glomerulonephritis_type_I of the Kidney". Archived fromthe original on 2006-09-10. Retrieved2008-11-25.Archived 2006-09-10 at theWayback Machine
- ↑"Renal Pathology".Archived from the original on 2017-09-01. Retrieved2008-11-25.Archived 2017-09-01 at theWayback Machine
- ↑West CD, McAdams AJ (March 1998). "Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III".Am. J. Kidney Dis.31 (3):427–34.doi:10.1053/ajkd.1998.v31.pm9506679.PMID 9506679.
- ↑"Final Diagnosis — Case 148".Archived from the original on 2020-11-29. Retrieved2008-11-25.Archived 2020-11-29 at theWayback Machine
- ↑Patrick D Walker; Franco Ferrario; Kensuke Joh; Stephen M Bonsib (2007)."Dense deposit disease is not a membranoproliferative glomerulonephritis".Modern Pathology.20 (6):605–616.doi:10.1038/modpathol.3800773.PMID 17396142.
- ↑Sethi S, Fervenza FC (2012). "Membranoproliferative glomerulonephritis - a new look at an old entity".N Engl J Med.366 (12):1119–1131.doi:10.1056/NEJMra1108178.PMID 22435371.
- ↑Rose KL, Paixao-Cavalcante D, Fish J, et al. (February 2008)."Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice".J. Clin. Invest.118 (2):608–18.doi:10.1172/JCI32525.PMC 2200299.PMID 18202746.
- ↑Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B (January 2007). "MPGN II--genetically determined by defective complement regulation?".Pediatr. Nephrol.22 (1):2–9.doi:10.1007/s00467-006-0299-8.PMID 17024390.
- ↑(reviewed in Appel et al., 2005; Smith et al., 2007). Smith, R. J. ., Harris, C. L., & Pickering, M. C. (2011). Dense Deposit Disease. Molecular Immunology, 48(14), 1604–1610.http://doi.org/10.1016/j.molimm.2011.04.005/Archived 2023-05-12 at theWayback Machine
- ↑Swainson CP, Robson JS, Thomson D, MacDonald MK (1983). "Mesangiocapillary glomerulonephritis: a long-term study of 40 cases".J. Pathol.141 (4):449–68.doi:10.1002/path.1711410404.PMID 6363655.
- ↑Colville D, Guymer R, Sinclair RA, Savige J (2003). "Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease")".Am. J. Kidney Dis.42 (2): E2–5.doi:10.1016/S0272-6386(03)00665-6.PMID 12900843.
- ↑Pickering, M. C., D’Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., … Cook, H. T. (2013). C3 glomerulopathy: consensus report. Kidney International, 84(6), 1079–1089.http://doi.org/10.1038/ki.2013.377Archived 2021-08-29 at theWayback Machine
- ↑Neary JJ, Conlon PJ, Croke D, et al. (August 2002)."Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1".J. Am. Soc. Nephrol.13 (8):2052–7.doi:10.1097/01.ASN.0000022006.49966.F8.PMID 12138136.Archived from the original on 2020-05-30. Retrieved2008-11-26.Archived 2020-05-30 at theWayback Machine
- ↑Neary J, Dorman A, Campbell E, Keogan M, Conlon P (July 2002). "Familial membranoproliferative glomerulonephritis type III".Am. J. Kidney Dis.40 (1): e1.1–e1.6.doi:10.1053/ajkd.2002.33932.PMID 12087587.
- ↑Harrison's principles of internal medicine (19th ed.). New York, NY: McGraw-Hill Companies, Inc. 2015. p. 1841.ISBN 978-0-07-180216-1.
{{cite book}}
:|access-date=
requires|url=
(help)
External links
Classification | |
---|---|
External resources |
- Glomerulonephritis, Membranoproliferative Types I, II, III ateMedicine
- Corchado, Johnny Cruz, Smith, Richard JH (July 2007)."Dense Deposit Disease/Membranoproliferative Glomerulonephritis Type II". In Pagon RA, Bird TD, Dolan CR, et al. (eds.).GeneReviews. Seattle WA: University of Washington.PMID 20301598.Archived from the original on 2019-02-17. Retrieved2019-05-06.
- Membranoproliferative_GNArchived 2020-10-01 at theWayback Machine atNephropathology tutorialArchived 2020-10-30 at theWayback Machine
- MP GN PathophysiologyArchived 2019-11-30 at theWayback Machine discusses the nephritic auto-antibodies/factors
- Pages with script errors
- Webarchive template wayback links
- CS1 maint: archived copy as title
- CS1 errors: access-date without URL
- All articles with unsourced statements
- Articles with unsourced statements from April 2019
- Articles with invalid date parameter in template
- Nephrology
- Hepatitis C virus-associated diseases
- RTT